Cyclophosphamide is a chemotherapy and immunosuppressant drug. It is often used as an adjuvant drug with other chemotherapy medications especially for leukemia and lymphomas. (These cancers include Hodgkin’s and non-Hodgkin's lymphoma, Burkitt’s lymphoma, chronic lymphocytic leukemia (CLL), chronic myelocytic leukemia (CML), acute myelocytic leukemia (AML), acute lymphocytic leukemia (ALL), t-cell lymphoma (mycosis fungoides), multiple myeloma, neuroblastoma, retinoblastoma, rhabdomyosarcoma, Ewing's sarcoma; breast, testicular, endometrial, ovarian, and lung cancers, and in conditioning regimens for bone marrow transplantation.)
Theory[edit | edit source]
Evidence[edit | edit source]
Norwegian Study - Cyclo/ME[edit | edit source]
There is no evidence for the use of the drug to treat ME/CFS.
A Norwegian group, led by the researchers, Dr. Øystein Fluge and Professor Olav Mella, who are studying Rituximab use in ME/CFS, are running a clinical trial, called CycloME. The trial will test the effects of cyclophosphamide on ME/CFS patients that have been non-responders to Rituximab.
Risks & safety[edit | edit source]
Costs & availability[edit | edit source]
Learn more[edit | edit source]
See also[edit | edit source]
References[edit | edit source]
- Clinical Trials - Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS) (CycloME)